PERIODS opens: the first properly powered trial of tirzepatide in PCOS

The University of Bonn and four collaborating German centers have opened enrollment in PERIODS, a randomized, double-blind, placebo-controlled phase 4 trial of tirzepatide in women with polycystic ovary syndrome (PCOS) who are overweight or have obesity ^[1]. The trial is registered on ClinicalTrials.gov as NCT07326111, and it is built to answer a reproductive question, not just a weight question ^[1].

PCOS is one of the most common hormonal conditions in women of reproductive age, and irregular or absent periods are among its defining features. Until now, most data on GLP-1-based drugs in PCOS have come from small studies or from weight-loss trials that measured cycles only as an afterthought. PERIODS is designed from the start around menstrual and ovulatory outcomes ^[1].

What the trial is testing

The study plans to enroll 198 premenopausal women aged 18 to 45 with a body mass index of at least 27 and a PCOS diagnosis based on the Rotterdam criteria ^[1]. Participants will be randomly assigned to tirzepatide or matching placebo, with neither participants nor investigators knowing the assignment ^[1].

Treatment runs 72 weeks in total: a 20-week escalation period, in which the dose is stepped up to each participant's maximum tolerated dose, followed by 52 weeks of maintenance at that dose ^[1].

The primary endpoint is the menstrual bleeding ratio measured across the final 52 weeks of treatment — in other words, how regularly participants bleed during the maintenance phase rather than during the dose ramp-up ^[1]. The key secondary endpoint is the number of ovulations, confirmed by weekly serum progesterone testing ^[1]. Weekly blood draws are a demanding but fairly rigorous way to document ovulation, since self-reported cycles and ovulation predictor kits can miss cycles where bleeding occurs without ovulation.

Primary completion is expected in December 2028 ^[1].

Tirzepatide is the molecule sold in the United States as Mounjaro and Zepbound. The trial is classified as phase 4, meaning it studies a drug that is already approved, though the registry record does not describe the medication as approved for PCOS anywhere. Several details are not spelled out in the available registry information, including the exact dose ceiling, the funding arrangement, contraception and pregnancy-avoidance requirements, and the full list of secondary endpoints such as weight, androgen levels or insulin resistance. Those specifics are not yet known from the sources here.

Why it matters for patients

Many women with PCOS are already taking or considering GLP-1 or dual GIP/GLP-1 medications, often prescribed for obesity or type 2 diabetes rather than for PCOS itself. Anecdotally, some report that their periods return. PERIODS is an attempt to find out whether that effect is real and measurable against placebo, and how large it is ^[1].

The endpoint choice matters. A trial that measures bleeding ratio and progesterone-confirmed ovulation can distinguish between a drug that simply causes weight loss and one that meaningfully changes reproductive function ^[1]. That distinction is relevant to women who want more predictable cycles, and potentially to those thinking about fertility — though the registry description frames the endpoints around menstrual function and ovulation, not pregnancy or live birth ^[1].

The timeline is long. With primary completion set for December 2028, results will not be available for roughly three years, and any regulatory label change would come later still, if at all ^[1]. In the meantime, decisions about these drugs in PCOS remain between patients and their clinicians, based on the existing approved uses.

The trial is enrolling in Germany, at the University of Bonn plus four collaborating sites, so US patients would not generally have access to it ^[1].

What happens next

Enrollment is underway now. Each participant will spend 72 weeks on treatment — 20 weeks escalating, 52 weeks maintaining ^[1]. Primary completion is scheduled for December 2028, with published results typically following months to years after that date ^[1].